

ICER's Evaluation of Alzheimer's Treatment Undervalues Key Groups

The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer's disease isn't worth its cost. But the economists omit several key considerations about the devastating neurodegenerative disease.

Patients.

By underestimating the cost of Alzheimer's, ICER undervalues the well-being of the 6.2 million Americans living with the disease.

Patients' Former Selves.


ICER fails to quantify the significant qualitative burden of Alzheimer's, including the "loss of self" that patients typically experience as they slowly lose their memories and independence.

Caregivers.

ICER assumes only one caregiver for each Alzheimer's patient, though caregiving responsibility is spread across family, friends and the community. ICER also fails to incorporate the emotional cost to caregivers, who often face extreme stress or depression.

Communities of Color.

ICER's calculations do not explicitly account for Alzheimer's disproportionate impact on communities of color.



ICER's oversights could lead to challenges for people who need access to treatment for Alzheimer's.



Institute for
Patient Access